Mutant p53 forms a complex with Sp1 on HIV-LTR DNA

被引:51
作者
Chicas, A
Molina, P
Bargonetti, J
机构
[1] CUNY Hunter Coll, Inst Biomolec Struct & Funct, New York, NY 10021 USA
[2] CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA
[3] CUNY, Grad Ctr, New York, NY 10021 USA
关键词
His273-p53; DNA binding; transcription; Sp1;
D O I
10.1006/bbrc.2000.3965
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Many mutants of p53 activate HIV-LTR driven transcription and promote HIV replication. The region of the HIV-LTR containing Sp1-binding sites is important for this effect. In this study we test the hypothesis that mutant p53 interacts with DNA-bound Sp1 and in this way can increase transcription from Sp1-dependent promoters. We have used the breast cancer cell line MDA-MB-468 that expresses endogenous mutant p53(His273) as our source of p53 protein. First, we demonstrated that this mutant p53 participates in activating transcription from the HIV-LTR by showing that HIV-LTR-directed transcription in MDA-MB-468 cells is inhibited in a dominant-negative manner by p53(Val135). Using HIV-LTR DNA affinity chromatography, me detected coelution of p53(His273) and Sp1. We also demonstrated that this mutant p53 binds sequence specifically to the super consensus sequence (SCS) and that Sp1 coeluted with p53(His273) from a column containing this site. These data indicate that p53(His273) can associate with DNA-bound Sp1 suggesting that activated HIV-LTR transcription associated with mutant p53 occurs through a DNA driven multi-protein complex. (C) 2000 Academic Press.
引用
收藏
页码:383 / 390
页数:8
相关论文
共 38 条
[1]   P53 CONTROLS BOTH THE G(2)/M AND THE G(1) CELL-CYCLE CHECKPOINTS AND MEDIATES REVERSIBLE GROWTH ARREST IN HUMAN FIBROBLASTS [J].
AGARWAL, ML ;
AGARWAL, A ;
TAYLOR, WR ;
STARK, GR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (18) :8493-8497
[2]   A PROTEOLYTIC FRAGMENT FROM THE CENTRAL REGION OF P53 HAS MARKED SEQUENCE-SPECIFIC DNA-BINDING ACTIVITY WHEN GENERATED FROM WILD-TYPE BUT NOT FROM ONCOGENIC MUTANT P53-PROTEIN [J].
BARGONETTI, J ;
MANFREDI, JJ ;
CHEN, XB ;
MARSHAK, DR ;
PRIVES, C .
GENES & DEVELOPMENT, 1993, 7 (12B) :2565-2574
[3]  
Bargonetti J, 1997, CELL MOL BIOL, V43, P935
[4]  
BORELLINI F, 1993, J BIOL CHEM, V268, P7923
[5]   PURIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF THE PROMOTER-SPECIFIC TRANSCRIPTION FACTOR, SPL [J].
BRIGGS, MR ;
KADONAGA, JT ;
BELL, SP ;
TJIAN, R .
SCIENCE, 1986, 234 (4772) :47-52
[6]  
CANNON JV, 1990, EMBO J, V9, P1595
[7]   MODULATION OF ACTIVITY OF THE PROMOTER OF THE HUMAN MDR1 GENE BY RAS AND P53 [J].
CHIN, KV ;
UEDA, K ;
PASTAN, I ;
GOTTESMAN, MM .
SCIENCE, 1992, 255 (5043) :459-462
[8]   MODULATION OF CELLULAR AND VIRAL PROMOTERS BY MUTANT HUMAN P53-PROTEINS FOUND IN TUMOR-CELLS [J].
DEB, S ;
JACKSON, CT ;
SUBLER, MA ;
MARTIN, DW .
JOURNAL OF VIROLOGY, 1992, 66 (10) :6164-6170
[9]   GAIN OF FUNCTION MUTATIONS IN P53 [J].
DITTMER, D ;
PATI, S ;
ZAMBETTI, G ;
CHU, S ;
TERESKY, AK ;
MOORE, M ;
FINLAY, C ;
LEVINE, AJ .
NATURE GENETICS, 1993, 4 (01) :42-46
[10]   THE TUMOR-SUPPRESSOR PROTEIN P53 STRONGLY ALTERS HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REPLICATION [J].
DUAN, LX ;
OZAKI, I ;
OAKES, JW ;
TAYLOR, JP ;
KHALILI, K ;
POMERANTZ, RJ .
JOURNAL OF VIROLOGY, 1994, 68 (07) :4302-4313